XORTX Announces US$5 Million Public Offering
Rhea-AI Summary
XORTX Therapeutics (NASDAQ:XRTX) priced a public offering of 2,659,574 common shares or pre-funded warrants at US$1.88 per share for expected gross proceeds of US$5 million before fees and expenses.
The pre-funded warrants are immediately exercisable at US$0.0001 and the offering is expected to close on or about May 15, 2026, subject to customary conditions and regulatory approvals.
AI-generated analysis. Not financial advice.
Positive
- Public offering expected to raise US$5 million in gross proceeds
- Pricing set at US$1.88 per common share or pre-funded warrant
- Pre-funded warrants immediately exercisable at US$0.0001 per share
- Registration statement on Form F-1 declared effective on May 13, 2026
Negative
- Equity offering implies potential share dilution for existing XRTX shareholders
- Gross proceeds of US$5 million before deducting fees and expenses
- Closing remains subject to customary conditions and regulatory approvals
Market Reaction – XRTX
Following this news, XRTX has declined 5.38%, reflecting a notable negative market reaction. Argus tracked a trough of -15.6% from its starting point during tracking. Our momentum scanner has triggered 3 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $2.21. This price movement has removed approximately $185K from the company's valuation.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Market Reality Check
Peers on Argus
Pre-news, XRTX was down 3.7% while key biotech peers showed mixed moves: AZTR -5.16%, QNRX -2.31%, ENTO -5.68%, versus JAGX +2.46% and TOVX +2.14%, suggesting a stock-specific dynamic around this financing.
Previous Offering Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Oct 29 | Equity offering close | Negative | +2.9% | Closing of US$1.1M registered direct offering with shares and pre-funded warrants. |
| Oct 21 | Equity offering pricing | Negative | -3.4% | Pricing of US$1.1M registered direct offering at US$0.63 per share. |
Past equity offerings produced mixed reactions, with one negative and one positive next-day move, indicating inconsistent trading responses to financings.
Over the past year, XORTX has repeatedly used registered offerings to fund operations. In October 2025, it announced and then closed a registered direct offering raising about US$1.1 million via common shares and pre-funded warrants issued under an effective Form F-3 shelf. Market reactions were inconsistent: the pricing announcement on Oct 21, 2025 saw shares fall, while the closing on Oct 29, 2025 saw a modest gain. Today’s larger US$5 million public offering continues this pattern of using equity-linked structures for capital needs.
Historical Comparison
XORTX’s prior two offering announcements saw an average next-day move of -0.25%, with one gain and one decline, showing historically muted and mixed reactions.
The company has repeatedly accessed equity markets via registered offerings and pre-funded warrants, moving from smaller raises of about US$1.1 million in 2025 to the current US$5 million public offering.
Market Pulse Summary
The stock is dropping -23.2% following this news. A negative reaction despite the capital raise fits concerns that repeated offerings and pre-funded warrants may be dilutive. Prior financing news showed a decline of 3.37% on one offering, so pressure around this US$5 million deal would be consistent with past skepticism. Investors may weigh the benefit of added cash against potential dilution and the company’s pattern of returning to equity markets.
Key Terms
pre-funded warrants financial
exercise price financial
registration statement regulatory
form f-1 regulatory
placement agent financial
prospectus regulatory
u.s. securities and exchange commission regulatory
AI-generated analysis. Not financial advice.
CALGARY, Alberta, May 14, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces the pricing of a public offering of 2,659,574 common shares (“Common Shares”) or common shares equivalents in lieu thereof (“Pre-Funded Warrants”) at an offering price of US
The Offering is expected to close on or about May 15, 2026, subject to satisfaction of customary closing conditions, including the receipt of all necessary regulatory approvals, including the approval of the TSX Venture Exchange.
E.F. Hutton & Co. is acting as exclusive placement agent for the Offering.
The securities described above are being offered pursuant to a registration statement on Form F-1 (File No. 333-290512), which was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on May 13, 2026. The Offering is being made only by means of the prospectus forming part of the effective registration statement relating to the Offering. A final prospectus relating to the Offering will be filed with the SEC. Copies of the final prospectus relating to the Offering may be obtained, when available, by contacting E.F. Hutton & Co., 745 Fifth Avenue, 34th Floor and PH, New York, NY 10151, or by email at efhcapitalmarkets@efhutton.com. Investors may also obtain these documents at no cost by visiting the SEC’s website at https://www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About XORTX Therapeutics Inc.
XORTX is a pharmaceutical company with three clinically advanced products in development: 1) our lead program XRx-026 program for the treatment of gout; 2) XRx-008 program for ADPKD; and 3) XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type 2 diabetic nephropathy and recently acquired VB4-P5 program, which is currently at the pre-IND stage of development and targets both rare and prevalent forms of kidney disease. XORTX is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications that improve the quality of life and health of individuals with gout and other important diseases.
For more information, please contact:
| Allen Davidoff, CEO | Nick Rigopulos, Director of Communications | |
| adavidoff@xortx.com | nick@alpineequityadv.com | |
| +1 403 455 7727 | +1 617 901 0785 | |
Neither the TSX Venture Exchange nor Nasdaq has approved or disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
Forward Looking Statements
This press release contains express or implied forward-looking statements pursuant to applicable securities laws. For example, XORTX is using forward-looking statements when it discusses the expected mix of securities offered, the timing of the closing of the Offering and the satisfaction of customary closing conditions of the Offering. These forward-looking statements and their implications are based on the current expectations of the management of XORTX only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The Offering may not occur, may be delayed or may be completed with different terms than are currently contemplated. Except as otherwise required by law, XORTX undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting XORTX is contained under the heading “Risk Factors” in XORTX’s Registration Statement on Form F-1 filed with the SEC, which is available on the SEC’s website, www.sec.gov (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada, which are available on www.sedarplus.ca.
